Ngf isoform for use in the treatment of ocular pathologies

Patent metadata

Field	Value
Publication number	US-2024424060-A1
Application number	US-202418763519-A
Country	US
Kind code	A1
Filing date	Jul 3, 2024
Priority date	Feb 5, 2021
Publication date	Dec 26, 2024
Grant date	—

Abstract

The present invention relates to the field of treatment of ocular pathologies by administration of a NGF, which comprises more than 50% by weight of the NGF isoform of SEQ ID NO: 1. Said NGF is particularly useful in the treatment of ocular pathologies where the proliferation and survival effect of NGF is desired and where the proapoptotic effect of p75NTR is detrimental.

First claim

1 - 15 . (canceled)

16 . A method for treating glaucoma in a subject, the method comprising administering nerve growth factor (NGF) to the eye of the subject, wherein said NGF comprises more than 50% by weight of the NGF isoform of SEQ ID NO: 1, relative to the total weight of all NGF isoforms comprised in said NGF.

17 . The method of claim 16 , wherein said NGF comprises at least 60% by weight of the NGF isoform of SEQ ID NO: 1, relative to the total weight of all NGF isoforms comprised in said NGF.

18 . The method of claim 16 , wherein said NGF comprises at least 70% by weight of the NGF isoform of SEQ ID NO: 1, relative to the total weight of all NGF isoforms comprised in said NGF.

19 . The method of claim 16 , wherein said NGF comprises at least 80% by weight of the NGF isoform of SEQ ID NO: 1, relative to the total weight of all NGF isoforms comprised in said NGF.

20 . The method of claim 16 , wherein said NGF comprises at least 90% by weight of the NGF isoform of SEQ ID NO: 1, relative to the total weight of all NGF isoforms comprised in said NGF.

21 . The method of claim 16 , wherein said NGF comprises at least 95% by weight of the NGF isoform of SEQ ID NO: 1, relative to the total weight of all NGF isoforms comprised in said NGF.

22 . The method of claim 16 , wherein said NGF comprises at least 98% by weight of the NGF isoform of SEQ ID NO: 1, relative to the total weight of all NGF isoforms comprised in said NGF.

23 . The method of claim 16 , wherein said NGF comprises at least 99% by weight of the NGF isoform of SEQ ID NO: 1, relative to the total weight of all NGF isoforms comprised in said NGF.

24 . The method of claim 16 , wherein said NGF comprises 100% by weight of the NGF isoform of SEQ ID NO: 1, relative to the total weight of all NGF isoforms comprised in said NGF.

25 . The method of claim 16 , wherein said NGF isoforms comprised in said NGF comprise or are selected from NGF isoforms of SEQ ID NOs: 1, 2, 3, and 4, or admixtures thereof.

26 . The method of claim 16 , wherein said NGF comprises NGF isoforms of SEQ ID NOs: 2, 3, or 4, or their admixtures, in total weight lower than 20% by weight, relative to the total weight of all NGF isoforms comprised in said NGF.

27 . The method of claim 16 , wherein said NGF comprises NGF isoforms of SEQ ID NOs: 2, 3, or 4, or their admixtures, in total weight lower than 10% by weight, relative to the total weight of all NGF isoforms comprised in said NGF.

28 . The method of claim 16 , wherein said NGF comprises NGF isoforms of SEQ ID NOs: 2, 3, or 4, or their admixtures, in total weight lower than 5% by weight, relative to the total weight of all NGF isoforms comprised in said NGF.

29 . The method of claim 16 , wherein said NGF comprises NGF isoforms of SEQ ID NO: 2, 3, or 4, or their admixtures, in total weight lower than 2% by weight, relative to the total weight of all NGF isoforms comprised in said NGF.

30 . The method of claim 16 , wherein said NGF comprises NGF isoforms of SEQ ID NO: 2, 3, or 4, or their admixtures, in total weight lower than 1% by weight, relative to the total weight of all NGF isoforms comprised in said NGF.

31 . The method of claim 16 , wherein said NGF isoform of SEQ ID NO: 1 does not contain any post-translational modification.

32 . The method of claim 16 , wherein said NGF is comprised within a pharmaceutical composition in a therapeutically effective amount, wherein the pharmaceutical composition further comprises at least one pharmaceutically acceptable excipient.

33 . The method of claim 32 , wherein the pharmaceutical composition is for ophthalmic use.

34 . The method of claim 33 , wherein the pharmaceutical composition is a liquid ophthalmic composition.

35 . The method of claim 34 , wherein the pharmaceutical composition is an ophthalmic aqueous liquid composition.

36 . The method of claim 35 , wherein the pharmaceutical composition is administered topically to the anterior segment of the eye.

37 . The method of claim 32 , wherein said NGF is present in said composition in a concentration ranging from about 0.0001% to about 0.5% w/v of the aqueous composition.

38 . The method of claim 32 , wherein said NGF is present in said composition in a concentration ranging from about 0.001% to about 0.1% w/v of the aqueous composition.

39 . The method of claim 32 , wherein said NGF is present in said composition in a concentration of about 0.002% w/v of the aqueous composition.

40 . The method of claim 32 , wherein said composition is administered to a posterior segment of the eye.

41 . The method of claim 16 , wherein said NGF is administered to the eye by intravitreal injection.

42 . The method of claim 32 , wherein said composition is administered to the eye by intravitreal injection.

Assignees

• Dompe Farm Spa

Inventors

• Aramini Andrea
• Amendola Pier Giorgio
• Sirico Anna
• D'Anniballe Gaetano
• Cattani Franca
• Allegretti Marcello
• Mantelli Flavio

Classifications

• A61P27/02

  Ophthalmic agents · CPC title

• A61K38/185 Primary

  Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3 · CPC title